2022 Ljubljana, Slovenia

IV-01 Nikolaos Alimpertis
Revising the assessment of bioequivalence in the light of finite absorption time (FAT) concept: The axitinib case
Thursday 15:00-16:30
IV-02 Rami Ayoun Alsoud
Model-based Allometric Scaling Approaches for Predicting Human Pharmacokinetics of CB 4332, a Therapeutic Complement Factor I Protein
Thursday 15:00-16:30
IV-03 Geraldine Celliere
A novel model-integrated design for bioequivalence of long acting injectables
Thursday 15:00-16:30
IV-04 Vanessa Baier
PBPK model-guided assessment of a liver function test
Thursday 15:00-16:30
IV-05 Pavel Balazki
PB-QSP model of type 2 diabetes for individualized prediction of treatment combination outcomes with metformin, DPP4i, and SGLT2i.
Thursday 15:00-16:30
IV-06 Sara Bettonte
Cabotegravir pharmacokinetics after oral and intramuscular administration using physiologically based pharmacokinetic modelling
Thursday 15:00-16:30
IV-07 Dominic Bräm
Opportunities of Covariate Data Imputation with Machine Learning for Pharmacometricians in R
Thursday 15:00-16:30
IV-08 Katherine Briceno
Feedforward neural network as a surrogate for the reinforcement learning action-value function in a model-informed precision dosing oncology application
Thursday 15:00-16:30
IV-09 Núria Buil Bruna
Can mAb dose selection in IBD be supported by public domain data from other immune-mediated inflammatory diseases?
Thursday 15:00-16:30
IV-10 Letizia Carrara
Prospective predictions of drug pharmacokinetics and food effect in pediatrics via PBPK modelling
Thursday 15:00-16:30
IV-11 Simon Carter
The development of artificial neural networks for the prediction of influential individuals and outlying individuals and their application during the model building process
Thursday 15:00-16:30
IV-12 Estelle Chasseloup
Comparison of seven NLMEM approaches to test for drug effect using real placebo data
Thursday 15:00-16:30
IV-13 Marylore Chenel
Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children
Thursday 15:00-16:30
IV-14 Suein Choi
Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients
Thursday 15:00-16:30
IV-15 Suein Choi
DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data
Thursday 15:00-16:30
IV-16 Pavlos Chrysafidis
Re-writing oral pharmacokinetics using physiologically based finite time pharmacokinetic (PBFTPK) models
Thursday 15:00-16:30
IV-17 Yumi Cleary
Physiologically-based pharmacokinetic modelling of basmisanil to evaluate CYP3A mediated victim and perpetrator drug-drug interaction propensity
Thursday 15:00-16:30
IV-18 Emmanuelle Comets
Conditional non-parametric bootstrap for non-linear mixed effect models
Thursday 15:00-16:30
IV-19 Marina Cuquerella Gilabert
Towards PBPK model development for oral absorption in PhysPK
Thursday 15:00-16:30
IV-20 Alessandro De Carlo
A Two-Stages Global Sensitivity Analysis in presence of correlated inputs: Application on a Tumor-in-host-growth Inhibition model based on the Dynamic Energy Budget theory
Thursday 15:00-16:30
IV-21 Thibaud Derippe
Accelerating robust virtual patient (VP) population generation by substituting ODE solving with simple parameter comparisons
Thursday 15:00-16:30
IV-22 Paul Matthias Diderichsen
Characterising the onset of response using public domain data and MBMA: application cases in Atopic Dermatitis and Psoriatic Arthritis
Thursday 15:00-16:30
IV-23 Tong Dominic
Comparing full Bayesian estimation to maximum a posteriori (MAP) Bayesian estimation in three routine clinical care scenarios
Thursday 15:00-16:30
IV-24 Julie Dudasova
Leveraging immunogenicity data and logistic regression for detection of covariate effects on vaccine efficacy
Thursday 15:00-16:30
IV-25 Jeroen Elassaiss-Schaap
Mixing of variability in the log-domain with normal-domain variability components may lead to biased estimation
Thursday 15:00-16:30
IV-26 Nivea M. F. Voelkner
Implementation of Estimation Step Refinements to Support Runtime Reduction for Model Building in NONMEM® 7
Thursday 15:00-16:30
IV-27 Laura Fuhr
Peeling the grapefruit – investigating the drug interaction potential of grapefruit juice as CYP3A4 inhibitor using physiologically-based pharmacokinetic modeling
Thursday 15:00-16:30
IV-28 Mohamed Gewily
Parametric and Non-Parametric Methods in Clinical Decision Making- A Comparison of Bias and Precision using Real Clinical Data
Thursday 15:00-16:30
IV-29 Sungwoo Goo
Explainable covariate screening method using Artificial Neural Network (ANN) for Non-linear Mixed Effect Modeling
Thursday 15:00-16:30
IV-30 Alzahra Hamdan
Automatic Development of Pharmacokinetic Structural Models – Pharmpy Model Search Tool
Thursday 15:00-16:30
IV-31 Zhe Huang
Comparison of PK models using normal and log-transformed scale data
Thursday 15:00-16:30
IV-32 Jasmine Hughes
PKPDposterior: R package for structured full-Bayesian model-informed precision dosing
Thursday 15:00-16:30
IV-33 Itziar Irurzun Arana
A Long-Short Term Memory Approach to Predicting Neutrophil Count in Patients Undergoing Drug Treatment
Thursday 15:00-16:30
IV-34 Martin Johnson
Developing a reinforcement learning algorithm to determine an optimal dosing regimen for cancer treatment
Thursday 15:00-16:30
IV-35 Niclas Jonsson
Efficient and relevant stepwise covariate model building for pharmacometrics
Thursday 15:00-16:30
IV-36 Christos Kaikousidis
Implementation of non-linear mixed effects models in NONMEM described by fractional differential equations.
Thursday 15:00-16:30
IV-37 Wojciech Krzyzanski
Pharmacodynamic age structured population model for cell trafficking
Thursday 15:00-16:30
IV-38 Chun Liu
Comparison of performances of the open-source R package “nlmixr” vs. Monolix for population pharmacokinetics of continuous infusion meropenem in patients with onco-hematological malignancies
Thursday 15:00-16:30
IV-39 Helena Loer
Dose Adaptations for Drug-Gene and Drug-Drug Interactions involving Clopidogrel – A Physiologically based Pharmacokinetic (PBPK) Modeling Approach
Thursday 15:00-16:30
IV-40 James Lu
Neural Ordinary Differential Equations for Tumor Dynamics Modeling and Overall Survival Predictions
Thursday 15:00-16:30
IV-41 Julia Macente
Application of Physiologically-Based Pharmacokinetics using Simcyp to predict the exposure to Valproic Acid in human milk and pediatrics
Thursday 15:00-16:30
IV-42 Fatima Zahra Marok
Physiologically-based pharmacokinetic modeling of drug-drug interactions with ketoconazole and its metabolite deacetyl-ketoconazole
Thursday 15:00-16:30
IV-43 Uri Nahum
Innovative Machine Learning Based Algorithm to Differentiate Between Diabetes Insipidus and Primary Polydipsia in Clinical Practice
Thursday 15:00-16:30
IV-44 Nina Nauwelaerts
Physiologically-Based Pharmacokinetic (PBPK) Modelling to Predict Human Milk Exposure to Sildenafil and Bosentan: a contribution from the ConcePTION Project
Thursday 15:00-16:30
IV-45 Morgane PHILIPP
Model-based bioequivalence approach: robustness to model misspecification for sparse pharmacokinetic bioequivalence studies
Thursday 15:00-16:30
IV-46 Fiona Plait
Physiologically Based Pharmacokinetic Modeling of a CYP3A4-Mediated Drug-Drug Interaction: Prediction of Victim of Induction, not Inhibition, with a Moderate Fraction Metabolized by CYP3A4
Thursday 15:00-16:30
IV-47 Alicja Puszkiel
A minimal PBPK model for plasma and cerebrospinal fluid pharmacokinetics of trastuzumab in patients with leptomeningeal carcinomatosis
Thursday 15:00-16:30
IV-48 Javier Reig-López
A Physiologically Based Pharmacokinetic Model for Open Acid and Lactone Forms of Atorvastatin and Its Two Metabolites
Thursday 15:00-16:30
IV-49 Davide Ronchi
Facing the limits of the genetic algorithms for covariate selection
Thursday 15:00-16:30
IV-50 Mark Sale
Comparison of Robustness and Efficiency of Four Machine Learning Algorithms for Identification of Optimal Population Pharmacokinetic Models
Thursday 15:00-16:30
IV-51 Ayatallah Saleh
Elucidating the complex pharmacokinetics of voriconazole leveraging a middle-out approach
Thursday 15:00-16:30
IV-52 Morwarid Shahhossini
Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock
Thursday 15:00-16:30
IV-53 Yesong Shin
Population pharmacokinetic modelling for enterohepatic circulation of leflunomide in healthy Korean
Thursday 15:00-16:30
IV-54 Florian Simon
Application of the Quantitative System Toxicology model of drug-induced liver injury DILIsym to evaluate the hepatotoxic potential of drugs in early development
Thursday 15:00-16:30
IV-55 Erik Sjögren
A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework
Thursday 15:00-16:30
IV-56 Victoria Smith
PKPDAI: Unlocking Pharmacokinetic Data from Tables with Natural Language Processing
Thursday 15:00-16:30
IV-57 Victor Sokolov
Deciphering the mechanisms of drug effects on cardiovascular system through semi-mechanistic modeling of preclinical telemetry data: a validation study
Thursday 15:00-16:30
IV-58 Britta Steffens
Assessment of sensitivity and specificity in the context of pharmacometrics-based decision support tools: application to hyperbilirubinemia in neonates
Thursday 15:00-16:30
IV-59 Vo Thanh
Covariate Modelling and Bayesian Inference for Physiologically Based Pharmacokinetic Models
Thursday 15:00-16:30
IV-60 Franziska Thoma
Simple and illustrative model to study Bayesian hierarchical modelling approaches for continued learning in model-informed precision dosing
Thursday 15:00-16:30
IV-61 Eunsol Yang
Prediction of gastric pH-mediated drug exposure changes using physiologically based pharmacokinetic modeling: A case study of itraconazole
Thursday 15:00-16:30